Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | PDE8B | O95263 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622817 | 0.85 | ALDH1A1 (0.33) | MAP4K4ALDH1A1HDAC1NR1H2SETD7 | |
| SCHEMBL30622860 | 0.82 | GPR119 (0.40) | MAP4K4SETD7UCHL1GPR119 | |
| SCHEMBL29308615 | 0.81 | KCNH2 (0.38) | ALDH1A1UCHL1GPR119 | |
| SCHEMBL29308625 | 0.78 | CSNK1D (0.39) | MAP4K4HDAC1SETD7 | |
| SCHEMBL24276764 | 0.77 | MAP4K4 (0.33) | MAP4K4HDAC1NR1H2SETD7NR1H3 | |
| SCHEMBL29308618 | 0.75 | SETD7 (0.31) | SETD7 | |
| SCHEMBL31616837 | 0.74 | NR1H2 (0.41) | MAP4K4ALDH1A1NR1H2PARP1 | |
| SCHEMBL34466050 | 0.74 | GRM5 (0.34) | MAP4K4ALDH1A1NR1H2SETD7UCHL1 | |
| SCHEMBL22279667 | 0.73 | MAP4K4 (0.39) | MAP4K4ALDH1A1HDAC1NR1H2UCHL1 | |
| SCHEMBL26026951 | 0.73 | GRM5 (0.36) | MAP4K4ALDH1A1NR1H2SETD7UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | MAP4K4 965/4885ALDH1A1 2354/4885HDAC1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.